Search | Clinical Trials Finder

Conditions: PSC
Interventions: Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Treatment-Resistant Depression
Interventions: MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: PE0139 Injection, Placebo; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Anniston, Alabama • Hialeah, Florida • Renton, Washington

Conditions: Neuropathic Pain
Interventions: Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hereditary Angioedema
Interventions: rhC1INH, Placebo (Saline); Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more

Conditions: Burn, Pain, Dissociation, Opioid
Interventions: Ketamine, 0.9% NaCl; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cystic Fibrosis
Interventions: Denufosol Tetrasodium (INS37217) Inhalation Solution, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 5 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 82
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 72 more

Conditions: Fever
Interventions: Ibuprofen, Normal Saline; Drug · Other
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 8
States / cities: Orlando, Florida • St Louis, Missouri • Greensboro, North Carolina + 4 more

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Efprezimod alfa, Saline; Biological · Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 16
States / cities: Los Angeles, California • Sacramento, California • Santa Ana, California + 9 more

Conditions: Acute Myeloid Leukemia
Interventions: Gemtuzumab ozogamicin, Mitoxantrone, Etoposide; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diphtheria
Interventions: S315, 0.9% Sodium Chloride (NaCl); Drug
Lead sponsor: MassBiologics; Other
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Respiratory Syncytial Virus Infections
Interventions: Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection); Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more

Conditions: Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions: Clesrovimab, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 2 Weeks to 8 Months
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more

Conditions: Nonalcoholic Steatohepatitis, NASH
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more

Conditions: COVID-19-Induced Parosmia
Interventions: Stellate Ganglion Block, Placebo Sham Injection; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
Interventions: Aloe Vera Mouthwash, Standard of Care; Dietary Supplement · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 3
States / cities: Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin

Conditions: Abnormalities, Cardiovascular
Interventions: Volanesorsen, Moxifloxacin, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Femoroacetabular Impingement, Chondral Lesions
Interventions: Platelet-rich plasma (PRP), Saline; Biological · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Brain Injury
Interventions: HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells); Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 14 Years to 78 Years
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuroblastoma
Interventions: Related donor transplant, Cord blood transplant, Busulfan, Thymoglobulin, Fludarabine; Procedure · Drug
Lead sponsor: Columbia University; Other
Eligibility: Up to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: MET233 and MET097, Placebo, MET097; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 381 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cough, Wheezing
Interventions: VR647 Inhalation System + VR647 Smart Card 3 Secs, VR647 Inhalation System + VR647 Smart Card 2 Secs, VR647 Inhalation System + VR647 Smart Card 4 Secs; Combination Product
Lead sponsor: Vectura Limited; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Mission Viejo, California • Plymouth, Minnesota • St Louis, Missouri + 2 more

Search by objective public record fields.

PET/MRI of Primary Sclerosing Cholangitis

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Low-Dose Ketamine Infusion During Burn Wound Care

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Stellate Ganglion Block for COVID-induced Parosmia

Prevention of Oral Mucositis in Adults in With Hematologic Malignancy

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip

Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy